Paul G. Gauger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Paul G. Gauger has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Gerard M. Doherty
Boston Medical Center, Boston University
4 shared publications Rebecca M. Minter
Department of Surgery, University of Michigan, Ann Arbor, Michigan
2 shared publications- Barbra S. Miller
Division of Endocrine Surgery, University of Michigan, Ann Arbor, MI, USA
1 shared publication - Bradley N. Reames
Division of Surgical Oncology, Department of Surgery, University of Nebraska Medical Center, Omaha, USA
1 shared publication - Christopher P. Magas
Department of Surgery, University of Michigan Health System, 2207 Taubman Center, 1500 E. Medical Center Dr., Ann Arbor, MI, 48109-5346, USA
1 shared publication Christopher P. Scally
Department of Surgery, University of Michigan, Ann Arbor, Michigan
1 shared publication
Latest Publications
- 1 November 2015
- Published by Elsevier in Journal of Surgical Education
- Vol. 72 (6) , e267-e273
Surgical Baseball Cards: Improving Patient- and Family-Centered Care
- 1 November 2015
- Published by Elsevier in Journal of Surgical Education
- Vol. 72 (6) , e267-e273
Surgical Baseball Cards: Improving Patient- and Family-Centered Care
- 1 July 2014
- Published by Elsevier in Journal of Surgical Education
- Vol. 71 (4) , 580-586
Preserving Operative Volume in the Setting of the 2011 ACGME Duty Hour Regulations
- 1 July 2014
- Published by Elsevier in Journal of Surgical Education
- Vol. 71 (4) , 580-586
Preserving Operative Volume in the Setting of the 2011 ACGME Duty Hour Regulations
- 3 January 2014
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 21 (5) , 1647-1652
Outcomes of Total Thyroidectomy with Therapeutic Central and Lateral Neck Dissection with a Single Dose of Radioiodine in the Treatment of Regionally Advanced Papillary Thyroid Cancer and Effects on Serum Thyroglobulin
Achieving an undetectable serum thyroglobulin (Tg) level (<1.0 ng/mL) after surgical and radioiodine treatment for papillary thyroid cancer (PTC) is associated with low recurrence rates and has been termed biochemical remission. This study aimed to determine the effectiveness of total thyroidectomy with therapeutic central and lateral neck dissection for regionally advanced (T1–4bN1bM0) PTC with regard to posttreatment Tg levels. This is a single-institution retrospective cohort study of patients with regionally advanced PTC initially treated with total thyroidectomy and therapeutic levels 2–7 neck dissection from 2002 to 2012. Pathologic findings, complications, serum Tg levels, and outcomes were analyzed. Sixty-one patients were initially treated with total thyroidectomy and therapeutic central and lateral neck dissection for PTC involving the lateral cervical nodes (N1b). The median number of lymph nodes excised and positive was 27 (range 5–112) and 9 (range 1–67), respectively. Extranodal extension occurred in 48 %. Radioiodine was administered after surgery with a median total dose of 150 mCi (range 30–244 mCi). Recurrent or persistent cervical disease occurred in 8 (13 %) and 3 (5 %) patients, respectively, and required additional radioiodine treatment in 2 and reoperative neck dissection in 10. Three patients developed new distant metastasis, and 1 died during the median follow-up of 20 months (range 1–109 months). Undetectable unstimulated Tg (<1.0 ng/mL) without clinically detectable recurrence was experienced in 68 % of patients with initial treatment. Biochemical remission can be experienced in most patients presenting with regionally advanced PTC with total thyroidectomy and compartment based therapeutic neck dissection followed by a single dose of radioiodine.
- 3 January 2014
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 21 (5) , 1647-1652
Outcomes of Total Thyroidectomy with Therapeutic Central and Lateral Neck Dissection with a Single Dose of Radioiodine in the Treatment of Regionally Advanced Papillary Thyroid Cancer and Effects on Serum Thyroglobulin
Achieving an undetectable serum thyroglobulin (Tg) level (<1.0 ng/mL) after surgical and radioiodine treatment for papillary thyroid cancer (PTC) is associated with low recurrence rates and has been termed biochemical remission. This study aimed to determine the effectiveness of total thyroidectomy with therapeutic central and lateral neck dissection for regionally advanced (T1–4bN1bM0) PTC with regard to posttreatment Tg levels. This is a single-institution retrospective cohort study of patients with regionally advanced PTC initially treated with total thyroidectomy and therapeutic levels 2–7 neck dissection from 2002 to 2012. Pathologic findings, complications, serum Tg levels, and outcomes were analyzed. Sixty-one patients were initially treated with total thyroidectomy and therapeutic central and lateral neck dissection for PTC involving the lateral cervical nodes (N1b). The median number of lymph nodes excised and positive was 27 (range 5–112) and 9 (range 1–67), respectively. Extranodal extension occurred in 48 %. Radioiodine was administered after surgery with a median total dose of 150 mCi (range 30–244 mCi). Recurrent or persistent cervical disease occurred in 8 (13 %) and 3 (5 %) patients, respectively, and required additional radioiodine treatment in 2 and reoperative neck dissection in 10. Three patients developed new distant metastasis, and 1 died during the median follow-up of 20 months (range 1–109 months). Undetectable unstimulated Tg (<1.0 ng/mL) without clinically detectable recurrence was experienced in 68 % of patients with initial treatment. Biochemical remission can be experienced in most patients presenting with regionally advanced PTC with total thyroidectomy and compartment based therapeutic neck dissection followed by a single dose of radioiodine.
- 12 February 2008
- Published by Wiley in World Journal of Surgery
- Vol. 32 (7) , 1285-1300
Evidence‐Based Surgical Management of Substernal Goiter
Background: A number of reports have been published concerning the surgical treatment of substernal goiters; however, there is yet to be a comprehensive review of this body of literature using evidence‐based methodology.Methods: This article is a systematic review of the literature using evidence‐based criteria and a review of unpublished data from our institution.Results: Issue 1. Limited level III/IV data suggest that the incidence of cancer in substernal goiters is not higher than the incidence of cancer in cervical goiters. Risk factors for malignancy in substernal goiters may include a family history of thyroid pathology, a history of cervical radiation therapy, recurrent goiter, and the presence of cervical adenopathy (grade C recommendation). Issue 2. Prospective level V data suggest that, for most patients, expert endocrine surgeons utilize an extracervical approach approximately 2% of the time to remove a substernal goiter safely; a sternotomy or thoracotomy appears more likely in cases of a primary substernal goiter or a mass larger than the thoracic inlet (no recommendation). Issue 3. There may be a higher rate of permanent hypoparathyroidism and unintentional permanent recurrent laryngeal nerve injury when total thyroidectomy is performed for removal of a substernal goiter than for removal of a cervical goiter alone (grade C recommendation). Injury of the external branch of the superior laryngeal nerve was not specifically addressed and is almost certainly underreported. Issue 4. The presence of a substernal goiter, especially being present more than 5 years and causing significant tracheal compression, is likely a risk factor for tracheomalacia and tracheostomy (grade C recommendation). Tracheomalacia with substernal goiter is an infrequent occurrence, and many cases of tracheomalacia can be managed without tracheostomy (no recommendation). Issue 5. Prospective level V data suggest that about 5% to 10% of operations for substernal goiters are performed because of recurrent or persistent disease, although retrospective level V data report an even higher rate, up to 37%. The most common initial operations with recurrence or persistence appear to be subtotal or hemithyroidectomy (no recommendation).Conclusion: Evidence‐based recommendations provide reliable information regarding the pathologic findings and operative management of substernal goiters in expert hands.
- 12 February 2008
- Published by Wiley in World Journal of Surgery
- Vol. 32 (7) , 1285-1300
Evidence‐Based Surgical Management of Substernal Goiter
Background: A number of reports have been published concerning the surgical treatment of substernal goiters; however, there is yet to be a comprehensive review of this body of literature using evidence‐based methodology.Methods: This article is a systematic review of the literature using evidence‐based criteria and a review of unpublished data from our institution.Results: Issue 1. Limited level III/IV data suggest that the incidence of cancer in substernal goiters is not higher than the incidence of cancer in cervical goiters. Risk factors for malignancy in substernal goiters may include a family history of thyroid pathology, a history of cervical radiation therapy, recurrent goiter, and the presence of cervical adenopathy (grade C recommendation). Issue 2. Prospective level V data suggest that, for most patients, expert endocrine surgeons utilize an extracervical approach approximately 2% of the time to remove a substernal goiter safely; a sternotomy or thoracotomy appears more likely in cases of a primary substernal goiter or a mass larger than the thoracic inlet (no recommendation). Issue 3. There may be a higher rate of permanent hypoparathyroidism and unintentional permanent recurrent laryngeal nerve injury when total thyroidectomy is performed for removal of a substernal goiter than for removal of a cervical goiter alone (grade C recommendation). Injury of the external branch of the superior laryngeal nerve was not specifically addressed and is almost certainly underreported. Issue 4. The presence of a substernal goiter, especially being present more than 5 years and causing significant tracheal compression, is likely a risk factor for tracheomalacia and tracheostomy (grade C recommendation). Tracheomalacia with substernal goiter is an infrequent occurrence, and many cases of tracheomalacia can be managed without tracheostomy (no recommendation). Issue 5. Prospective level V data suggest that about 5% to 10% of operations for substernal goiters are performed because of recurrent or persistent disease, although retrospective level V data report an even higher rate, up to 37%. The most common initial operations with recurrence or persistence appear to be subtotal or hemithyroidectomy (no recommendation).Conclusion: Evidence‐based recommendations provide reliable information regarding the pathologic findings and operative management of substernal goiters in expert hands.
- 31 May 2007
- Published by Wiley in World Journal of Surgery
- Vol. 31 (8) , 1716-1717
Letter to the Editor
- 31 May 2007
- Published by Wiley in World Journal of Surgery
- Vol. 31 (8) , 1716-1717
Letter to the Editor
- 1 April 2005
- Published by Elsevier in The American Journal of Surgery
- Vol. 189 (4) , 479-487
Initial use of a novel instrument to measure professionalism in surgical residents
- 1 April 2005
- Published by Elsevier in The American Journal of Surgery
- Vol. 189 (4) , 479-487
Initial use of a novel instrument to measure professionalism in surgical residents
- Open Access
- 1 February 2004
- Published by American Medical Association (AMA) in Archives of Surgery
- Vol. 139 (2) , 164-169
An Alternative Analysis of Intraoperative Parathyroid Hormone Data May Improve the Ability to Detect Multiglandular Disease
Intraoperative parathyroid hormone (IOPTH) monitoring as an adjunct to parathyroidectomy has an important role in minimally invasive parathyroidectomy, yet it serves a less certain role in a standard open parathyroid gland exploratory procedure. Optimal interpretation of IOPTH level kinetic data in the discrimination of single gland (SG) disease and multiglandular (MG) disease has not been entirely defined and is under scrutiny. The inability of IOPTH monitoring to detect remaining enlarged parathyroid glands after removal of a single hypersecreting gland in up to 55% of these cases is certainly not an actual deficiency of the measurement technique itself.1 Two plausible alternative explanations exist. The first possibility is that these data may merely reflect an aspect of MG primary hyperparathyroidism that requires a shift in the accepted pathophysiologic paradigm. This is to say that not all enlarged parathyroid glands are hypersecretory (ie, size is not immutably linked to hyperfunction). The second possibility is that our current method of data analysis may not be optimal in terms of sensitivity and specificity. Many different variations in data interpretation criteria exist, but one has become most common.2 Although standard analysis of IOPTH data has been based on extensive operative experience, the arithmetic considerations are admittedly somewhat arbitrary. Analysis includes normalization of all values to the individual baseline value (usually the highest of either postincision or preexcision values). A fall to below 50% of the baseline value by 10 minutes after adenoma excision is considered to reflect biochemical cure and this criterion (also known as the 50% rule) is widely used.3,4 This 50% rule is easy to use, but it is not universally accepted. Libutti et al5 have suggested that a kinetic analysis based on first-order decay characteristics may be more reflective of the true disappearance of circulating parathyroid hormone (PTH) levels after excision of a hypersecreting parathyroid gland and that such an approach can account for individual variations in PTH half-life levels and the variability in timing of the postexcision blood samples. This study attempted to define the influence of the background or residual PTH levels that may contribute in a variable manner to the PTH level disappearance rates after excision of a single abnormal parathyroid gland.
- 1 February 2004
- Published by American Medical Association (AMA) in Archives of Surgery
- Vol. 139 (2) , 164-169
Open AccessAn Alternative Analysis of Intraoperative Parathyroid Hormone Data May Improve the Ability to Detect Multiglandular Disease
Intraoperative parathyroid hormone (IOPTH) monitoring as an adjunct to parathyroidectomy has an important role in minimally invasive parathyroidectomy, yet it serves a less certain role in a standard open parathyroid gland exploratory procedure. Optimal interpretation of IOPTH level kinetic data in the discrimination of single gland (SG) disease and multiglandular (MG) disease has not been entirely defined and is under scrutiny. The inability of IOPTH monitoring to detect remaining enlarged parathyroid glands after removal of a single hypersecreting gland in up to 55% of these cases is certainly not an actual deficiency of the measurement technique itself.1 Two plausible alternative explanations exist. The first possibility is that these data may merely reflect an aspect of MG primary hyperparathyroidism that requires a shift in the accepted pathophysiologic paradigm. This is to say that not all enlarged parathyroid glands are hypersecretory (ie, size is not immutably linked to hyperfunction). The second possibility is that our current method of data analysis may not be optimal in terms of sensitivity and specificity. Many different variations in data interpretation criteria exist, but one has become most common.2 Although standard analysis of IOPTH data has been based on extensive operative experience, the arithmetic considerations are admittedly somewhat arbitrary. Analysis includes normalization of all values to the individual baseline value (usually the highest of either postincision or preexcision values). A fall to below 50% of the baseline value by 10 minutes after adenoma excision is considered to reflect biochemical cure and this criterion (also known as the 50% rule) is widely used.3,4 This 50% rule is easy to use, but it is not universally accepted. Libutti et al5 have suggested that a kinetic analysis based on first-order decay characteristics may be more reflective of the true disappearance of circulating parathyroid hormone (PTH) levels after excision of a hypersecreting parathyroid gland and that such an approach can account for individual variations in PTH half-life levels and the variability in timing of the postexcision blood samples. This study attempted to define the influence of the background or residual PTH levels that may contribute in a variable manner to the PTH level disappearance rates after excision of a single abnormal parathyroid gland.
- Open Access
- 1 November 2003
- Published by American Medical Association (AMA) in Archives of Surgery
- Vol. 138 (11) , 1214-1218
Appearance of Ectopic Undescended Inferior Parathyroid Adenomas on Technetium Tc 99m Sestamibi Scintigraphy
Research from JAMA Surgery — Appearance of Ectopic Undescended Inferior Parathyroid Adenomas on Technetium Tc 99m Sestamibi Scintigraphy — A Lesson From Reoperative Parathyroidectomy
- 1 November 2003
- Published by American Medical Association (AMA) in Archives of Surgery
- Vol. 138 (11) , 1214-1218
Open AccessAppearance of Ectopic Undescended Inferior Parathyroid Adenomas on Technetium Tc 99m Sestamibi Scintigraphy
Research from JAMA Surgery — Appearance of Ectopic Undescended Inferior Parathyroid Adenomas on Technetium Tc 99m Sestamibi Scintigraphy — A Lesson From Reoperative Parathyroidectomy
- 29 April 2003
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 90 (6) , 748-754
Role of endoscopic ultrasonography in screening and treatment of pancreatic endocrine tumours in asymptomatic patients with multiple endocrine neoplasia type 1
Background Patients with multiple endocrine neoplasia (MEN) type 1 risk premature death from pancreatic endocrine tumours (PETs). Endoscopic ultrasonography (EUS) is the most sensitive imaging modality for small PETs. A screening and therapeutic approach for asymptomatic patients is delineated in which EUS plays a pivotal role. Methods This was a retrospective study of 15 patients with MEN-1 but with no symptoms of a PET. All patients underwent serum hormone measurement, including gastrin, and EUS. The findings were used to facilitate operative treatment. Results Six of 15 patients had a normal basal gastrin level and nine had a raised level. EUS demonstrated PETs in 14 patients and identified multiple lesions in 12. There was no predictive relationship between age or gastrin level and the number or size of PETs discovered. Thirteen patients have undergone enucleation or resection of PETs and two remain under observation. Nine of the 13 patients underwent transduodenal exploration to excise gastrinoma(s). One patient had lymph node metastases found at operation. There was no death. Self-limiting pancreatic fistula in five patients and biliary fistula in one. Conclusion Early and aggressive screening using EUS identifies PETs in asymptomatic patients with MEN-1. Detection of tumours at an early stage, before the development of symptoms, lymph node metastases or liver metastases, may facilitate prompt surgical intervention and improve prognosis.
- 29 April 2003
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 90 (6) , 748-754
Role of endoscopic ultrasonography in screening and treatment of pancreatic endocrine tumours in asymptomatic patients with multiple endocrine neoplasia type 1
Background Patients with multiple endocrine neoplasia (MEN) type 1 risk premature death from pancreatic endocrine tumours (PETs). Endoscopic ultrasonography (EUS) is the most sensitive imaging modality for small PETs. A screening and therapeutic approach for asymptomatic patients is delineated in which EUS plays a pivotal role. Methods This was a retrospective study of 15 patients with MEN-1 but with no symptoms of a PET. All patients underwent serum hormone measurement, including gastrin, and EUS. The findings were used to facilitate operative treatment. Results Six of 15 patients had a normal basal gastrin level and nine had a raised level. EUS demonstrated PETs in 14 patients and identified multiple lesions in 12. There was no predictive relationship between age or gastrin level and the number or size of PETs discovered. Thirteen patients have undergone enucleation or resection of PETs and two remain under observation. Nine of the 13 patients underwent transduodenal exploration to excise gastrinoma(s). One patient had lymph node metastases found at operation. There was no death. Self-limiting pancreatic fistula in five patients and biliary fistula in one. Conclusion Early and aggressive screening using EUS identifies PETs in asymptomatic patients with MEN-1. Detection of tumours at an early stage, before the development of symptoms, lymph node metastases or liver metastases, may facilitate prompt surgical intervention and improve prognosis.